Related news:
Cipla's M K Hamied steps down as VC - Cipla promoters to sell 2.5% for Rs 2,650 crore - Cipla promoters to sell 2.5% for Rs2,650cr - Cipla, Glenmark recall drugs from US market: USFDA
Cipla
Bookmark
ShareCipla is a company. It is located in Mumbai, India and was founded in 1935. The company is part of the Health Care sector, specifically in the Pharmaceuticals industry.
Key facts
- city: Mumbai
- country: India
- sector: Health Care
- industry: Pharmaceuticals
- foundation year: 1935
- CEO: Umang Vohra
- CEO gender: Male
Classified as: organization
Business
Cipla is one of the companies in India, companies in Pharmaceuticals, companies in Health Care and 3,466,499 companies in our database.
- Assets: 3.4B $
- Employees:
Try Pro to see estimates
- Market cap: 10.7B $
- Profits: 318M $
- Revenues: 2.7B $
Stocks from Cipla:
Talking Points:
- CiplaLeading Global Pharmaceutical Company
- Built on the foundation of caring for life, Cipla ensures access to quality & affordable medicines through 1500+ products across various therapeutic categories.
- Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935.
- Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For over 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries. Our portfolio includes over 1000 products across wide range of therapeutic ...
- Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other dosage forms consists of injectables and biosimilars. Cipla Limited has collaboration with CSIR-Indian Institute of Chemical Technology for the development of medication for the treatment of COVID-19; partnership with Karwa Ltd. for the commercialization of antibody detection kits for COVID-19; partnership with the Premier Medical Corporation Private Limited for the commercialization of the rapid antigen test kits for COVID-19; licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir. The company was incorporated in 1935 and is headquartered in Mumbai, India.
Learn more about talking points
